Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2018

View Archived Issues

Microbiome affects rotavirus vaccine immunogenicity

TAC versus CAR

RAPTA-T pretreatment enhances tumor vascular function and cisplatin uptake in pleural mesothelioma

Discovery of a biomarker that correlates with psychopathy and cognition in schizophrenia

Identification of a gene that drives progression and metastases in KRAS-driven lung cancer

Preclinical studies identify a potential drug target for the treatment of neuroblastoma

First patient treated in Escalier Biosciences' phase I/IIa study of ESR-114

Entasis announces positive topline phase II data for ETX-2514 plus sulbactam in patients with cUTI

Brain immune cells mediate arthritic joint pain

IND approval received in China for phase Ib/III study of CAN-017 as treatment of ESCC

Hefei Institutes of Physical Sciences divulges EZH2 inhibitors

Proteasome inhibitors patented by Chengdu Origin Biotechnology

Shanghai Longwood Biopharmaceuticals identifies hepatitis B caspid assembly inhibitors

Nuclear receptor ROR-gamma inverse agonists discovered at Genfit

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical describe TLR7 agonists

First patients dosed in phase I/II study of TLC-590 for postsurgical pain management

BHV-0223 reduces anxiety in proof-of-concept trial

Kalydeco approved in U.S. for cystic fibrosis in patients aged 12 to < 24 months

Phase II trial of AG-013 in oral mucositis resumes

Cabotegravir/rilpivirine regimen shows noninferiority to three-drug regimen for HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...